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Sequencing of the human genome has greatly impacted the
proteomics-based analysis of disease by providing a frame-
work for understanding the proteome of diseased cells,
tissues, and biological ﬂuids. Consequently, there is a grow-
ing interest in applying proteomics technologies to deﬁne
proteinpathwaysinvolvedinvariousdiseases,toidentifynew
biomarkers that correlate with diseases, ideally in their early
stages, and to accelerate the development of new therapeutic
targets. However, disease-related proteomics applications
require that we improve our ability to separate and charac-
terize the components of complex protein mixtures in such a
way as to boost both throughput and sensitivity. In response
to these demands, the proteomics technologies have been
improved markedly over recent years. Today, proteomics,
in all its various forms, is proving to be invaluable to our
understanding of the biochemistry of health and disease and
will likely play a central role in the evolution of personalized
medicine. In this special issue, we include reports of novel
research ﬁndings together with several reviews that highlight
advances in key areas.
The ﬁrst two papers of this special issue focus on lung
cancer. The ﬁrst paper, by H. C. Gong et al., addresses the
proﬁling of receptor tyrosine kinase pathway activation and
the role of key genetic mutations in human lung tumor
cell lines and human lung tumors. The authors deﬁned
molecular pathways which may assist in development of
targeted lung tumor therapies. Within the second paper,
Q. Zhang et al. used proteomic proﬁling to delineate
expression and subcellular localization of multiple forms of
aldehyde dehydrogenase in lung adenocarcinoma cell lines.
The next two papers focus on pancreatic cancer. The third
paper, by R. S. Kwon and D. M. Simeone, reviews the use of
protein-based biomarkers for the diagnosis of cystic tumors
of the pancreas. The fourth paper, by M. Abulaizi et al.,
utilizes a three-step proteomic protocol (immunodepletion
of abundant serum proteins, followed by fractionation by
RP-HPLC and further separation by 2D-PAGE) to discover
candidate early detection biomarkers of pancreatic cancer.
The next two papers focus on breast cancer, with the
ﬁfth paper, by D. E. Misek and E. H. Kim, reviewing the
development of protein biomarkers for the early detection
of breast cancer. The sixth paper, by J. He et al., addresses
LC-MS/MS identiﬁcation of protein biosignatures in breast
tumors, as protein-based markers that correctly classify
tumor subtypes and predict therapeutic response would be
of great clinical utility in guiding patient treatment. The next
two papers are both by M. S. Sabel et al., and focus on
melanoma. The seventh paper reviews the use of proteomics
for the discovery of new prognostic and predictive biomark-
ers. The eighth paper explores the clinical utility of serum
autoantibodiesthatweredetectedinmelanomapatients.The
investigators proﬁled serum antibodies against melanoma-
associated antigens to identify those that may predict nodal
positivity, a widely accepted index of metastatic disease.
The ninth paper, by E. H. Kim and D. E. Misek, reviews
the use of glycoproteomics to identify cancer biomarkers.
The tenth paper, by A. Vivekanandan-Giri et al., uti-
lized glycoproteomics to identify novel urinary glycoprotein
biomarkers of chronic kidney disease. The issue concludes
with two papers that report on novel approaches and related
considerations. The eleventh paper, by I. Kiyokawa et al.,
describes the development of a new surface coating for
urinary collection tubes that minimizes the amount of urine
protein adsorption onto the walls of the collection tube.2 International Journal of Proteomics
Within the ﬁnal paper of this special issue, T. Hagiwara
et al. examine the utility of a solid-phase hexapeptide ligand
libraryincombinationwithconventionalplasmaproteomics
modalities for comprehensive proﬁling of intact plasma
proteins.
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